Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma
HemaSphere · 2026-06 · 10 (6)
DOI: 10.1002/hem3.70396 ↗Kurz gefasst
Leserbrief in der Zeitschrift HemaSphere, online erschienen am 07.06.2026. Verfasst von Gala Vega und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology, START Madrid-FJD Hospital Fundación Jimenez Diaz Madrid Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Bispecific antibodies have shown unprecedented efficacy in relapsed refractory multiple myeloma (RRMM). 1 – 4 While bispecific antibody (bsAb) therapy is currently administered indefinitely until disease progression or intolerance, there is a subset of patients with RRMM who have prolonged remission, off treatment after a finite duration of bsAb therapy. 5 We previously reported sustained remission after a limited duration of bsAb therapy in 23 patients, with an 18 ‐ month progression free survival (PFS) rate of 70%. 5 Here, we report sustained remission, humoral immune reconstitution, and infection risk off treatment in a larger cohort of patients treated across multiple centers with a finite duration of bsAb exposure and extended follow ‐ up. Patients included in this analysis received bsAb, either as standard of care or in a clinical trial, and discontinued therapy for reasons other than disease progression or death and had at least 3 months of ongoing remission following treatment discontinuation. While the requirement for a minimum of 3 months of sustained remission off ‐ therapy was chosen somewhat arbitrarily, it was grounded
Autor:innen und Institutionen
- Hematology and Oncology, START Madrid-FJD Hospital Fundación Jimenez Diaz Madrid Spain.
- Department of Internal Medicine University Hospital of Würzburg Würzburg Germany.
- Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands.
- Division of Blood Disorders Rutgers Cancer Institute New Brunswick New Jersey USA.
- Division of Hematology University of Utah Salt Lake City Utah USA.
- Department of Hematology, Hospital Clínic de Barcelona Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Barcelona Spain.
ORCID-Profile: Febe Smits, Ghulam Rehman Mohyuddin, Carolina Schinke, Rajshekhar Chakraborty, Meera Mohan
Zitieren
APA
Vega, G., Morillo, D., Riedhammer, C., Smits, F., Bag, A., Julian, K., Gomis, N. T., Gaisan, C. M., Bermudez, M. A., Shah, M. R., Mohyuddin, G. R., Dhakal, B., Rasche, L., Schinke, C., D'Souza, A., Szabo, A., van de Donk, N. W. C. J., Chakraborty, R., & Mohan, M. (2026). Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma. HemaSphere, 10(6). https://doi.org/10.1002/hem3.70396
Vancouver
Vega G, Morillo D, Riedhammer C, Smits F, Bag A, Julian K, et al. Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma. HemaSphere. 2026;10(6). doi:10.1002/hem3.70396
BibTeX
@article{Vega2026,
author = {Vega, Gala and Morillo, Daniel and Riedhammer, Christine and Smits, Febe and Bag, Aishee and Julian, Kelly and Gomis, Natalia Tovar and Gaisan, Carmen Montes and Bermudez, Maria Aranzazu and Shah, Mansi R and Mohyuddin, Ghulam Rehman and Dhakal, Binod and Rasche, Leo and Schinke, Carolina and D'Souza, Anita and Szabo, Aniko and van de Donk, Niels W C J and Chakraborty, Rajshekhar and Mohan, Meera},
title = {Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {6},
doi = {10.1002/hem3.70396}
}
EUVIMED